MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2023-008516 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Iñaki Eguren-Santamaria und 14 weiteren Autor:innen. Beteiligte Einrichtung: Immunology and Immunotherapy, Centro de Investigación Médica Aplicada, Pamplona, Spain. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CRIS Cancer Foundation, Instituto de Salud Carlos III, Fundación Científica Asociación Española Contra el Cáncer.
Abstract (Originalsprache)
Background
Immunodeficient mice engrafted with peripheral blood mononuclear cells (PBMCs) are models to study new cancer immunotherapy agents. However, this approach is associated with xenograft-versus-host disease (xGVHD), which starts early after PBMC transfer and limits the duration and interpretation of experiments. Here, we explore different approaches to overcome xGVHD and better support the development of cancer immunotherapies.
Methods
Immunodeficient NOD-scid IL2Rg null (NSG) mice were intravenously transferred with human PBMCs and subcutaneously co-engrafted with HT29 human colon carcinoma cells. Diverse strategies to reduce xGVHD while preserving the antitumor activity of human immune cells were evaluated: (1) ex vivo immune graft modification by depleting CD4 + T cells pre-transfer using magnetic beads, (2) post-transplantation cyclophosphamide administration to eliminate proliferating xenoreactive T-cell clones and (3) using major histocompatibility complex (MHC) class I and II-deficient NSG mice: (K b D b ) null (IA) null (MHC-dKO NSG). Body weight and plasma murine alanine aminotransferase levels were measured as indicators of xGVHD and tumor size was measured every 2–3 days to monitor antitumor activity. The antitumor effects and pharmacodynamics of nivolumab plus ipilimumab and an anti-epithelial cell adhesion molecule (EpCAM)/CD3 T-cell engager (αEpCAM/CD3 bispecific antibody (BsAb)) were evaluated in the model.
Results
CD4 + T-cell depletion attenuates xGVHD but also abrogates the antitumor activity. Cyclophosphamide limits the antitumor response and does not substantially prevent xGVHD. In contrast, xGVHD was significantly attenuated in MHC-dKO NSG recipients, while the antitumor effect of human PBMCs was preserved. Furthermore, the administration of nivolumab plus ipilimumab caused exacerbated xGVHD in conventional NSG mice, thereby precluding the observation of their antitumor effects. Severe xGVHD did not occur in MHC-dKO NSG mice thus enabling the study of complete and durable tumor rejections. Similarly, NSG mice treated with an αEpCAM/CD3 BsAb showed complete tumor regressions, but died due to xGVHD. In contrast, MHC-dKO NSG mice on treatment with the αEpCAM/CD3 BsAb achieved complete tumor responses without severe xGVHD. A significant proportion of mice rendered tumor-free showed tumor rejection on rechallenge with HT29 cells without further treatment. Finally, tumor-infiltrating CD8 + T-cell number increase, activation and CD137 upregulation were observed on αEpCAM/CD3 BsAb treatment.
Conclusion
Humanized MHC-dKO immunodeficient mice allow and refine the preclinical testing of immunotherapy agents for which experimentation is precluded in conventional immunodeficient mice due to severe xGVHD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immunology and Immunotherapy, Centro de Investigación Médica Aplicada, Pamplona, Spain.
- Medical Oncology Department, Clínica Universidad de Navarra, Pamplona, Spain.
- Instituto de Investigación Sanitaria de Navarra, Paplona, Spain.
- CIC energiGUNE, Alava, Spain.
- Clinical Trial Unit, Clínica Universidad de Navarra, Pamplona, Spain.
- Department of Preventive Medicine and Public Health, Universidad de Navarra, Pamplona, Spain.
ORCID-Profile: Iñaki Eguren-Santamaria, Pedro Berraondo, Ignacio Melero
Förderung
- CRIS Cancer Foundation
- Instituto de Salud Carlos III
- Fundación Científica Asociación Española Contra el Cáncer
- Spanish Ministry of Science and Innovation
- Mark Foundation For Cancer Research
- Fundació Marató de TV3
- Fundación Fero
- Instituto de Salud Carlos III/Fondo Europeo de Desarrollo Regional
Zitieren
APA
Eguren-Santamaria, I., Fernández de Piérola, E., Camps, G., Martín-Muñoz, P., Campos, M., Cuculescu, D., Aguilera-Buenosvinos, I., Rodríguez López, I., Salido-Vallejo, R., Alexandru, R., De Andrea, C. E., Álvarez-Gigli, L., Berraondo, P., Melero, I., & Sanmamed, M. F. (2024). MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-008516
Vancouver
Eguren-Santamaria I, Fernández de Piérola E, Camps G, Martín-Muñoz P, Campos M, Cuculescu D, et al. MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2023-008516
BibTeX
@article{EgurenSantamaria2024,
author = {Eguren-Santamaria, Iñaki and Fernández de Piérola, Eva and Camps, Gracián and Martín-Muñoz, Paula and Campos, María and Cuculescu, Doina and Aguilera-Buenosvinos, Inmaculada and Rodríguez López, Inmaculada and Salido-Vallejo, Rafael and Alexandru, Raluca and De Andrea, Carlos E and Álvarez-Gigli, Laura and Berraondo, Pedro and Melero, Ignacio and Sanmamed, Miguel F},
title = {MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2023-008516}
}
EUVIMED